EUVIMEDScopri EUVIMED
Crossref

FDG PET/CT–based Response Assessment in Malignancies

Ashwin Singh Parihar iD, Farrokh Dehdashti iD, Richard L Wahl iD

RadioGraphics · 2023-04-01 · 43 (4)

DOI: 10.1148/rg.220122 ↗

At a glance

Journal article in RadioGraphics, published on 2023-04-01. Written by Ashwin Singh Parihar and 2 co-authors. Institution: From the Mallinckrodt Institute of Radiology (A.S.P., F.D., R.L.W.) and Siteman Cancer Center (F.D., R.L.W.), Washington University School of Medicin…. Major MEDLINE topics: Positron Emission Tomography Computed Tomography, Neoplasms. Cited 55 times so far (Crossref); 55 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Response is the logical outcome measure of a treatment in a clinical or research setting. Objective response assessment involves the use of a test to segregate patients who are likely to experience improved survival from those who are not. Early and accurate response assessment is critical for determining therapy effectiveness in clinical settings, for effective trial designs comparing two or more therapies, and for modulating treatment on the basis of response (ie, response-adapted therapy). 2-[fluorine 18]fluoro-2-deoxy-d-glucose (FDG) PET/CT can provide both functional and structural information about a disease process. It has been used at several stages of patient management, including imaging-based tumor response assessment, for various malignancies. FDG PET/CT can be used to differentiate patients with lymphoma who have a residual mass but no residual disease after treatment (ie, complete responders) from those who have a residual mass and residual disease after treatment. Similarly, in solid malignancies, the functional changes in glucose uptake and metabolism precede the structural changes (commonly seen as tumor shrinkage) and necrosis. Response assessment criteria have been developed on the basis of findings on FDG PET/CT images and are continuously being revised to ensure standardization and improve their predictive performance. Published under a CC BY 4.0 license. Quiz questions for this article are available through the Online Learning Center.

Subjects

MeSH terms (MEDLINE)

Positron Emission Tomography Computed TomographyNeoplasmsHumansFluorodeoxyglucose F18RadiopharmaceuticalsPositron-Emission Tomography

Substances

Fluorodeoxyglucose F18Radiopharmaceuticals

Authors and institutions

  • From the Mallinckrodt Institute of Radiology (A.S.P., F.D., R.L.W.) and Siteman Cancer Center (F.D., R.L.W.), Washington University School of Medicine, 4525 Scott Ave, East Building, #3433, St Louis, MO 63110.

ORCID profiles: Ashwin Singh Parihar, Farrokh Dehdashti, Richard L Wahl

Cite

APA

Parihar, A. S., Dehdashti, F., & Wahl, R. L. (2023). FDG PET/CT–based Response Assessment in Malignancies. RadioGraphics, 43(4). https://doi.org/10.1148/rg.220122

Vancouver

Parihar AS, Dehdashti F, Wahl RL. FDG PET/CT–based Response Assessment in Malignancies. RadioGraphics. 2023;43(4). doi:10.1148/rg.220122

BibTeX
@article{Parihar2023,
  author = {Parihar, Ashwin Singh and Dehdashti, Farrokh and Wahl, Richard L},
  title = {FDG PET/CT–based Response Assessment in Malignancies},
  journal = {RadioGraphics},
  year = {2023},
  volume = {43},
  number = {4},
  doi = {10.1148/rg.220122}
}
Start for free →